达格列净佐治心力衰竭并2型糖尿病临床研究  

Clinical Study of Dapagliflozin in the Adjunctive Treatment of Heart Failure Complicated withDiabetes Mellitus Type 2

作　　者：黎叶飞[1] 郑扣龙[1] 盛臻强[1] LI Yefei;ZHENG Koulong;SHENG Zhenqiang(The Second Affiliated Hospital of Nantong University,Nantong,Jiangsu,China 226001)

机构地区：[1]南通大学第二附属医院,江苏南通226001

出　　处：《中国药业》2023年第22期111-114,共4页China Pharmaceuticals

基　　金：江苏省卫生健康委医学科研立项项目[Z2021005]。

摘　　要：目的 探讨达格列净佐治射血分数保留心力衰竭(HFpEF)并2型糖尿病(T2DM)的临床疗效。方法 选取医院2018年1月至2019年12月收治的HFpEF并T2DM患者160例,按用药方案的不同分为对照组(77例)和观察组(83例)。两组患者均予常规对症治疗,观察组患者加服达格列净片。两组均连续治疗24个月。结果 观察组患者治疗6,12,18,24个月时的二尖瓣口舒张早期E波的峰值流速(E)/舒张晚期A波的峰值流速(A)显著高于对照组(P <0.05),左心室舒张末期内径(LVEDd)及左心室收缩末期内径(LVESd)均显著小于对照组(P <0.05);观察组治疗后的窦性心率震荡斜率(TS)显著高于对照组(P <0.05),窦性心率震荡初始(TO)值显著低于对照组(P <0.05)。两组患者低血压、恶心呕吐、皮肤瘙痒、低血糖、泌尿生殖道感染等不良反应发生率无显著差异(P> 0.05)。结论 达格列净佐治HFpEF并T2DM,可有效抑制患者的心脏重构,改善心脏功能,促进窦性心率震荡发生异常的恢复。Objective To investigate the clinical efficacy of dapagliflozin in the adjunctive treatment of heart failure with preserved ejection fraction(HFpEF)complicated with diabetes mellitus type 2(T2DM).Methods A total of 160 patients with HFpEF and T2DM admitted to the hospital from January 2018 to December 2019 were selected and divided into the control group(77 cases)and the observation group(83 cases)according to different medication regimens.Both groups were given routine symptomatic treatment,on this basis,the patients in the observation group were given Dapagliflozin Tablets(orally).Both groups were treated continuously for 24 months.Results The peak flow velocity of early diastolic E wave(E)/peak flow velocity of late diastolic A wave(A)of mitral valve orifice in the observation group at 6,12,18,24 months after treatment was significantly higher than that in the control group(P<0.05),and the left ventricular end-diastolic diameter(LVEDd)and left ventricular end-systolic diameter(LVESd)were significantly lower than those in the control group(P<0.05).The turbulence slope(TS)in the observation group after treatment was significantly higher than that in the control group(P<0.05),and the turbulence onset(TO)was significantly lower than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions such as hypotension,nausea,vomiting,skin itching,hypoglycemia,urinary and genital tract infection between the two groups(P>0.05).Conclusion Dapagliflozin in the adjunctive treatment of HFpEF complicated with T2DM can effectively inhibit cardiac remodeling,improve cardiac function,promote recovery of heart rate turbulence(HRT)abnormalities in patients.

关 键 词：射血分数保留心力衰竭 2型糖尿病 达格列净 心功能 窦性心率震荡 药品不良反应 

分 类 号：R969.4[医药卫生—药理学] R541.6[医药卫生—药学]